Solventum Q4 2024: GAAP EPS $0.17, adj. EPS $1.41, organic sales +2.3%

Solventum Corp

2024-FY EPS reported $2.76 revenue$8,254,000,000

GAAP diluted EPS $0.17; adjusted EPS $1.41; sales $2,074M (+1.9% reported, +2.3% organic).
GAAP operating income $136M (6.6% margin); adjusted $422M (20.4% margin); MedSurg and Dental drove growth.
Generated $219M cash from operations; free cash flow $92M.
Full-year 2024: sales $8,254M, GAAP EPS $2.76, adjusted EPS $6.70, free cash flow $805M.
Introduced FY 2025 guidance for organic sales growth, adjusted EPS, and free cash flow (specific figures not provided).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.